Mycenax Biotech (4726) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.031x

Based on the latest financial reports, Mycenax Biotech (4726) has a cash flow conversion efficiency ratio of -0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.35 Million ≈ $-1.59 Million USD) by net assets (NT$1.64 Billion ≈ $51.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Mycenax Biotech to measure how much of total assets are equity-financed.

Mycenax Biotech - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how Mycenax Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Mycenax Biotech earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Mycenax Biotech Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Mycenax Biotech ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jr Global Reit KO:348950	N/A
Nabors Energy Transition Corp. II Class A Ordinary Shares NASDAQ:NETD	-0.004x
Zen Voce TWO:3581	-0.017x
BJC Heavy Industries Public Company Limited BK:BJCHI	0.054x
Lan Fa Textile Co Ltd TW:1459	0.027x
Dongkook Ind KO:001620	0.135x
Paramount Corporation Bhd KLSE:1724	0.064x
Astec LifeSciences Limited NSE:ASTEC	-0.020x

Annual Cash Flow Conversion Efficiency for Mycenax Biotech (2017–2024)

The table below shows the annual cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Mycenax Biotech.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$2.02 Billion ≈ $63.75 Million	NT$-191.68 Million ≈ $-6.04 Million	-0.095x	-76.72%
2023-12-31	NT$2.45 Billion ≈ $77.10 Million	NT$-131.18 Million ≈ $-4.13 Million	-0.054x	-10.84%
2022-12-31	NT$3.11 Billion ≈ $97.84 Million	NT$-150.19 Million ≈ $-4.73 Million	-0.048x	+36.95%
2021-12-31	NT$1.91 Billion ≈ $60.07 Million	NT$-146.23 Million ≈ $-4.61 Million	-0.077x	-153.36%
2020-12-31	NT$1.21 Billion ≈ $38.17 Million	NT$174.17 Million ≈ $5.49 Million	0.144x	+212.55%
2019-12-31	NT$1.10 Billion ≈ $34.72 Million	NT$-140.74 Million ≈ $-4.43 Million	-0.128x	+35.74%
2018-12-31	NT$907.01 Million ≈ $28.58 Million	NT$-180.27 Million ≈ $-5.68 Million	-0.199x	-399.11%
2017-12-31	NT$1.14 Billion ≈ $36.04 Million	NT$-45.55 Million ≈ $-1.44 Million	-0.040x	--

About Mycenax Biotech

TWO:4726 Taiwan Biotechnology

Market Cap

$158.05 Million

NT$5.02 Billion TWD

Market Cap Rank

#17389 Global

#869 in Taiwan

Share Price

NT$24.20

Change (1 day)

+0.21%

52-Week Range

NT$24.00 - NT$39.65

All Time High

NT$68.00